Trial record 1 of 1 for:    AGS-003-007
Previous Study | Return to List | Next Study

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01582672
Recruitment Status : Terminated (Lack of efficacy)
First Posted : April 23, 2012
Last Update Posted : June 14, 2018
Information provided by (Responsible Party):
Argos Therapeutics

Brief Summary:
This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.

Condition or disease Intervention/treatment Phase
Advanced Renal Cell Carcinoma Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Drug: Standard Treatment Biological: AGS-003 Phase 3

Detailed Description:
This study will investigate the combination of an autologous ribonucleic acid (RNA) electroporated dendritic cell (DC) based immunotherapy, AGS-003, plus standard treatment (initiating with sunitinib). The primary objective in this study is to determine the median OS achieved by this combination compared to the OS resulting from use of active control (standard treatment), in a population of adults with advanced renal cell carcinoma (RCC), with nephrectomy indicated, and with remaining metastatic disease.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 462 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
Study Start Date : November 2012
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AGS-003 + Standard Treatment
Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
Biological: AGS-003
Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.

Active Comparator: Standard Treatment
Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
Drug: Standard Treatment
Standard treatment for Renal Cell Carcinoma
Other Name: Sunitinib

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: From date of subject randomization to date of death; assessed up to 42 months or until 290 deaths have been accrued on study ]
    Duration from randomization to death

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: From date of subject randomization to date of progression; assessed up to 42 months ]
  2. Tumor Response [ Time Frame: From date of subject randomization to date of progression; assessed up to 42 months ]
    Monitor for evidence of the following tumor responses: Objective response rate, Duration of overall response, and Disease control rate.

  3. Monitor treatment emergent adverse events between both arms [ Time Frame: From safety baseline until either meeting a discontinuation criterion or death; assessed up to 42 months ]
    Compare adverse events between both arms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria for Tumor Collection:

  1. Diagnosis or clinical signs of advanced RCC
  2. Scheduled for cytoreductive or partial nephrectomy

Key Exclusion Criteria for Tumor Collection:

  1. Known inability to undergo sunitinib treatment as currently labeled, due to pre-existing medical conditions
  2. Requirement for systemic chronic immunosuppressive drugs or corticosteroids
  3. Evidence of brain metastases prior to nephrectomy

Key Inclusion Criteria for Treatment Study:

  1. Advanced disease, histologically assessed as RCC, with predominantly clear cell histology
  2. Metastatic disease (measurable or non-measurable) that can be monitored throughout the course of the study participation per RECIST 1.1
  3. Subjects who are candidates for standard first-line therapy initiating with sunitinib
  4. Time from diagnosis to treatment < 1 year
  5. Karnofsky performance status (KPS) ≥ 70%
  6. Life expectancy of 6 months or greater
  7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
  8. Adequate hematologic, renal, hepatic, and coagulation function
  9. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug
  10. Normal ECG or clinically non-significant finding(s) at Screening
  11. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study
  12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Key Exclusion Criteria for Treatment Study:

  1. Prior systemic therapy (including adjuvant or neoadjuvant) of any kind for RCC, including immunotherapy, chemotherapy, hormonal, or investigational therapy
  2. Prior history of malignancy within the preceding 3 years, except for adequately treated in situ carcinomas or non-melanoma skin cancer, adequately treated early stage breast cancer, superficial bladder cancer, and non-metastatic prostate cancer with a normal PSA
  3. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease
  4. Patients with 4 or more of the following risk factors:

    1. Hgb < LLN
    2. Corrected calcium > 10.0 mg/dL
    3. KPS < 80%
    4. Neutrophils > ULN
    5. Platelets > ULN
  5. Planned or elective surgical treatment post-nephrectomy for the direct management of RCC, within 28 days before Visit 1 (Week 0)
  6. NCI CTCAE Grade 3 hemorrhage < 28 days before Visit 1 (Day 0)
  7. Clinically significant cardiovascular conditions within 3 months prior to Randomization
  8. Significant gastrointestinal abnormalities
  9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  10. Active autoimmune disease or condition requiring chronic immunosuppressive therapy
  11. Clinically significant infections, including human immunodeficiency virus, syphilis, and active hepatitis B or C
  12. Current treatment with an investigational therapy on another clinical trial
  13. Pregnancy or breastfeeding
  14. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01582672

  Hide Study Locations
United States, Arizona
Scottsdale, Arizona, United States, 85259
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
La Jolla, California, United States, 92093
Los Angeles, California, United States, 90024
Los Angeles, California, United States, 90048
San Francisco, California, United States, 94115
United States, Colorado
Aurora, Colorado, United States, 80045
Colorado Springs, Colorado, United States, 80909
Denver, Colorado, United States, 80211
United States, Florida
Miami, Florida, United States, 33140
Tampa, Florida, United States, 33612
United States, Georgia
Atlanta, Georgia, United States, 30322
Augusta, Georgia, United States, 30912
Marietta, Georgia, United States, 30060
United States, Idaho
Boise, Idaho, United States, 83706
Meridian, Idaho, United States, 83642
United States, Illinois
Chicago, Illinois, United States, 60612
Maywood, Illinois, United States, 60153
Springfield, Illinois, United States, 62702
United States, Indiana
Greenwood, Indiana, United States, 46143
Indianapolis, Indiana, United States, 46202
Indianapolis, Indiana, United States, 46237
United States, Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
Kansas City, Kansas, United States, 66160
Wichita, Kansas, United States, 67226
United States, Louisiana
Metairie, Louisiana, United States, 70006
New Orleans, Louisiana, United States, 70112
New Orleans, Louisiana, United States, 70121
United States, Maryland
Baltimore, Maryland, United States, 21201
Baltimore, Maryland, United States, 21204
United States, Massachusetts
Boston, Massachusetts, United States, 02114
Burlington, Massachusetts, United States, 01805
United States, Michigan
Detroit, Michigan, United States, 48201
Detroit, Michigan, United States, 48202
Grand Rapids, Michigan, United States, 49503
Lansing, Michigan, United States, 48912
United States, Minnesota
Minneapolis, Minnesota, United States, 55455
Rochester, Minnesota, United States, 55905
United States, Missouri
Saint Louis, Missouri, United States, 63110
United States, Nebraska
Omaha, Nebraska, United States, 68114
Omaha, Nebraska, United States, 68130
Omaha, Nebraska, United States, 68198
United States, New Hampshire
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Hackensack, New Jersey, United States, 07601
United States, New Mexico
Albuquerque, New Mexico, United States, 87131
United States, New York
Albany, New York, United States, 12208
East Syracuse, New York, United States, 13057
New Hyde Park, New York, United States, 11040
New York, New York, United States, 10016
New York, New York, United States, 10029
Stony Brook, New York, United States, 11794
Syracuse, New York, United States, 13210
United States, North Carolina
Charlotte, North Carolina, United States, 28204
Durham, North Carolina, United States, 27710
Raleigh, North Carolina, United States, 27607
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cincinnati, Ohio, United States, 45212
Middletown, Ohio, United States, 45042
Toledo, Ohio, United States, 43623
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Portland, Oregon, United States, 97213
Portland, Oregon, United States, 97239
Springfield, Oregon, United States, 97477
United States, Pennsylvania
Allentown, Pennsylvania, United States, 18103
Danville, Pennsylvania, United States, 17822
Easton, Pennsylvania, United States, 18045
Hershey, Pennsylvania, United States, 17033
Philadelphia, Pennsylvania, United States, 19111
Philadelphia, Pennsylvania, United States, 19140
Pittsburgh, Pennsylvania, United States, 15212
Pittsburgh, Pennsylvania, United States, 15232
United States, Rhode Island
Providence, Rhode Island, United States, 02906
United States, South Carolina
Charleston, South Carolina, United States, 29425
Greenville, South Carolina, United States, 29605
Myrtle Beach, South Carolina, United States, 29572
United States, South Dakota
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
Nashville, Tennessee, United States, 37215
United States, Texas
Dallas, Texas, United States, 75231
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 78229
San Antonio, Texas, United States, 78240
United States, Utah
Salt Lake City, Utah, United States, 84132
United States, Virginia
Charlottesville, Virginia, United States, 22908
Virginia Beach, Virginia, United States, 23462
United States, Washington
Seattle, Washington, United States, 98101
Seattle, Washington, United States, 98109
United States, Wisconsin
Milwaukee, Wisconsin, United States, 53215
Milwaukee, Wisconsin, United States, 53226
Canada, Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Ontario
Hamilton, Ontario, Canada, L8N4A6
London, Ontario, Canada, N6A5W9
Oshawa, Ontario, Canada, L1G 2B9
Ottawa, Ontario, Canada, K1H8L6
Canada, Quebec
Greenfield Park, Quebec, Canada, J4V2HI
Montreal, Quebec, Canada, H2L4M1
Montreal, Quebec, Canada, H3T1E2
Quebec, Canada, G1R3S1
Hradec Kralove, Czechia, 50005
Liberec, Czechia, 46063
Olomouc, Czechia, 77520
Prague, Czechia, 10034
Praha 8, Czechia, 18081
Budapest, Hungary, H-1062
Budapest, Hungary, H-1122
Debrecen, Hungary, H-4032
Haifa, Israel, 31096
Jerusalem, Israel, 91120
Kfar Saba, Israel, 44281
Rehovot, Israel, 76100
Tel Hashomer, Israel, 52621
Zerifin, Israel, 70300
Roma, Italy, 00152
Rome, Italy, 00144
Badalona, Spain, 08916
Barcelona, Spain, 08003
Barcelona, Spain, 08035
Madrid, Spain, 28033
Madrid, Spain, 28046
Madrid, Spain, 28050
Sevilla, Spain, 41013
Valencia, Spain, 46009
Vigo, Spain, 36204
United Kingdom
Cambridge, United Kingdom, CB20QQ
Norwich, United Kingdom, NR47UY
Preston, United Kingdom, PR29HT
Sponsors and Collaborators
Argos Therapeutics
Principal Investigator: Robert Figlin, MD, FACP Cedars-Sinai Medical Center
Principal Investigator: Christopher G Wood, MD, FACP M.D. Anderson Cancer Center

Responsible Party: Argos Therapeutics Identifier: NCT01582672     History of Changes
Other Study ID Numbers: AGS-003-007
2012-000871-17 ( EudraCT Number )
First Posted: April 23, 2012    Key Record Dates
Last Update Posted: June 14, 2018
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Argos Therapeutics:
Kidney Cancer

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases